by Michael Masciadrelli,Yale UniversityCirculating tumor antigen reactive T cells in patients with advanced melanoma. Credit:Nature Immunology(2024). DOI: 10.1038/s41590-024-02023-4Y
by Michael Masciadrelli,Yale UniversityCirculating tumor antigen reactive T cells in patients with advanced melanoma. Credit:Nature Immunology(2024). DOI: 10.1038/s41590-024-02023-4Y
Credit: Pixabay/CC0 Public DomainScientists in the United Kingdom have created a world-first urine test that could indicate the first possible signs of lung cancer.Lung cancer is the third most common
Credit: Pixabay/CC0 Public DomainScientists in the United Kingdom have created a world-first urine test that could indicate the first possible signs of lung cancer.Lung cancer is the third most common
by Justin Jackson , Medical XpressGraphical abstract. Credit:Cell(2024). DOI: 10.1016/j.cell.2024.10.042Institute of Immunobiology-led research has made a significant breakthrough in under
by Justin Jackson , Medical XpressGraphical abstract. Credit:Cell(2024). DOI: 10.1016/j.cell.2024.10.042Institute of Immunobiology-led research has made a significant breakthrough in under
byUniversity of PittsburghCredit: Etatics Inc. from PexelsOpioids are often first-line treatments for cancer-related pain, but they can suppress the immune system and reduce the effectiveness of
byUniversity of PittsburghCredit: Etatics Inc. from PexelsOpioids are often first-line treatments for cancer-related pain, but they can suppress the immune system and reduce the effectiveness of
byKarolinska InstitutetCredit: Unsplash/CC0 Public DomainToday, women with estrogen-sensitive breast cancer receive anti-hormonal therapy. Researchers now show that postmenopausal women with low
byKarolinska InstitutetCredit: Unsplash/CC0 Public DomainToday, women with estrogen-sensitive breast cancer receive anti-hormonal therapy. Researchers now show that postmenopausal women with low
by Elana GotkineAutologous hematopoietic cell transplant (auto-HCT) is not beneficial for patients with mantle cell lymphoma (MCL) in first complete remission (CR) with undetectable minimal residual d
by Elana GotkineAutologous hematopoietic cell transplant (auto-HCT) is not beneficial for patients with mantle cell lymphoma (MCL) in first complete remission (CR) with undetectable minimal residual d
byPeter MacCallum Cancer CentreCredit: Pixabay/CC0 Public DomainA breakthrough by researchers at Peter Mac will allow scientists to detect, analyze and profile cancer tumors in patients via a si
byPeter MacCallum Cancer CentreCredit: Pixabay/CC0 Public DomainA breakthrough by researchers at Peter Mac will allow scientists to detect, analyze and profile cancer tumors in patients via a si
byUniversity of Strathclyde, GlasgowCredit: Pixabay/CC0 Public DomainA new Scotland-wide toolkit is supporting the collection of patient-reported outcome measures (PROMs) to understand the impac
byUniversity of Strathclyde, GlasgowCredit: Pixabay/CC0 Public DomainA new Scotland-wide toolkit is supporting the collection of patient-reported outcome measures (PROMs) to understand the impac
byThe Wistar InstituteCredit: Unsplash/CC0 Public DomainThe Wistar Institute's David B. Weiner, Ph.D.—Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Sm
byThe Wistar InstituteCredit: Unsplash/CC0 Public DomainThe Wistar Institute's David B. Weiner, Ph.D.—Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Sm